CalAmp (Nasdaq: CAMP), an advanced technology solutions company, has signed a strategic collaboration with Cryoport (Nasdaq: CYRX) (Nasdaq: CYRXW), a temperature-controlled logistics company dedicated to the life sciences industry.
It was reported yesterday that the collaboration is aimed at developing a next generation condition monitoring system to further assure the security of global temperature controlled pharmaceutical shipments. This research and development collaboration is aimed at improving the protection and preservation of critical life science shipments, which demonstrates CalAmp's continued momentum in the supply chain visibility market and Cryoport's commitment to providing the most advanced best-in-class, data-driven solutions to its biopharmaceutical client base.
Along with CalAmp, Cryoport is exploring an advanced supply chain visibility service that will monitor, in real-time, environmental readings for regenerative medicine product shipments using Bluetooth sensor technology. If successful, the combination of the Cryoport Express Shippers and the Cryoportal Logistics Management Platform, coupled with CalAmp's new-to-market SC iOn Tag Bluetooth sensor technology and SC iOn Command platform, is to allow Cryoport to offer another advanced logistics solution that would pro-actively manage supply chain visibility across multi-mode global shipping routes.
Ipsen appoints new board director
Coiled Therapeutics completes enrolment in two AO-252 formulation cohorts
MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion
Kemp Proteins partners with NeuImmune to advance precision protein production
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
ProBio and Kun Tuo collaborate to deliver integrated CDMO-CRO solutions for advanced therapies
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Sobi and Innate confirm strategic partnership
Viatris receives Japanese approval for WAKIX in narcolepsy and sleep apnoea
WHO identifies SynAct Pharma's resomelagon among six dengue drug candidates
Japan approves subcutaneous Leqembi formulation for early Alzheimer's disease
Japan approves Lundbeck's eptinezumab for preventive migraine treatment
Skyhawk Therapeutics reports final results from Phase 1/2 trial in Huntington's disease